Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I).
Margaret E MacyRajen J ModyJoel M ReidJin PiaoLauren SaguiligTodd A AlonzoStacey L BergElizabeth FoxBrenda J WeigelDouglas S HawkinsMargaret M MooneyP Mickey WilliamsDavid R PattonBrent D CoffeySinchita Roy-ChowdhuriNaoko TakebeJames V TricoliKatherine A JanewayNita L SeibelDonald Williams ParsonsPublished in: JCO precision oncology (2024)
orally daily was tolerable in this heavily pretreated cohort. No objective responses were observed in this histology-agnostic biomarker-selected population with treatment-refractory solid tumors, demonstrating that pathway alteration alone is insufficient in pediatric cancers to generate a response to palbociclib monotherapy.